Loading company…
REGENXBIO Inc., based in Rockville, develops gene therapies using its NAV Technology Platform for common and rare diseases.
Founded in 2008 in Rockville, US, REGENXBIO Inc. is a biotechnology company developing gene therapies with its NAV Technology Platform for common and rare diseases. Its candidates include ABBV-RGX-314 for retinal diseases, RGX-202 for Duchenne muscular dystrophy and RGX-121 for MPS II. The company raised USD 138.6 mn in its IPO on September 16, 2015. The profile lists it at the Series D stage.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in